kabutan

ASKA Pharma, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 3%, Oct-Dec Ordinary Profit Decreases by 16%

Mon Feb 3, 2025 3:30 pm JST Earnings

4886 ASKA Pharmaceutical Holdings Co.,Ltd. 【J-GAAP】

Earnings Report

ASKA Pharmaceutical Holdings Co.,Ltd. <4886> [TSE Prime] announced its financial results after the market closed on February 3rd (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2025 (April to December) decreased 3.3% from the same period last year to 5.44 billion yen. The progress rate toward the full-year plan of 6.7 billion yen was 81.3%, below the five-year average of 98.0%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the January to March period (4Q) is expected to expand 40.7% from the same period last year, reaching 1.25 billion yen.

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit decreased to 2.13 billion yen, a 15.8% decrease compared to the same period last year. The operating profit margin decreased from 14.4% in the same period last year to 12.2%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2022 47,259 5,041 5,246 4,183 148.2 100.3 Feb 6, 2023 J-GAAP
Apr - Dec, 2023 48,824 5,526 5,631 6,458 228.1 86.3 Feb 5, 2024 J-GAAP
Apr - Dec, 2024 49,926 5,495 5,446 4,098 144.6 81.3 Feb 3, 2025 J-GAAP
YoY +2.3% -0.6% -3.3% -36.5% -36.6%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 31,195 3,445 3,426 3,416 120.7 20 May 10, 2024 J-GAAP
Oct - Mar, 2024 Guidance 30,629 3,355 3,388 2,440 86.0 25 Nov 5, 2024 J-GAAP
YoY -1.8% -2.6% -1.1% -28.6% -28.7%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 60,461 5,108 5,232 4,238 150.1 16 May 11, 2023 J-GAAP
Mar, 2024 62,843 6,500 6,522 7,545 266.5 40 May 10, 2024 J-GAAP
Mar, 2025 Guidance 63,000 6,700 6,700 5,000 176.3 50 May 10, 2024 J-GAAP
YoY +0.2% +3.1% +2.7% -33.7% -33.9%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2023 17,176 2,471 2,535 2,329 82.3 14.4 Feb 5, 2024 J-GAAP
Jan - Mar, 2024 14,019 974 891 1,087 38.4 6.9 May 10, 2024 J-GAAP
Apr - Jun, 2024 16,352 1,758 1,813 1,273 45.0 10.8 Aug 5, 2024 J-GAAP
Jul - Sep, 2024 16,019 1,587 1,499 1,287 45.4 9.9 Nov 5, 2024 J-GAAP
Oct - Dec, 2024 17,555 2,150 2,134 1,538 54.3 12.2 Feb 3, 2025 J-GAAP
YoY +2.2% -13.0% -15.8% -34.0% -34.0%

Related Articles